Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

医学 赛马鲁肽 中止 荟萃分析 置信区间 不利影响 超重 可信区间 系统回顾 相对风险 梅德林 减肥 频数推理 随机对照试验 需要治疗的数量 肥胖 随机效应模型 临床试验 物理疗法 内科学 绝对风险降低 科克伦图书馆 儿科 重症监护医学 循证医学
作者
Kailei Nong,Qingyang Shi,Xinran Xie,Yang Wang,Arnav Agarwal,Gordon H Guyatt,Haojie Zhang,Yiyuan Gao,Kamlesh Khunti,Carel Wynand le Roux,Indah Suci Widyahening,Qinlin Fan,Tianyou Liu,Yunhe Mao,Iván D. Flórez,Heyue Du,Xiaohui Pan,Xinyu Zou,Chaoyang Wang,Xiaodong Sun
出处
期刊: [BMJ]
卷期号:394: e372161-e372161 被引量:21
标识
DOI:10.1136/bmj-2026-372161
摘要

OBJECTIVE: To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients. DESIGN: Systematic review and network meta-analysis of 24 outcomes using frequentist random effects models and bayesian dose-response models, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, and the Cochrane Risk of Bias 2 tool. DATA SOURCES: Medline, Embase, and Cochrane Library, searched up to 12 November 2025. STUDY SELECTION: Randomised controlled trials of 12 weeks' duration or longer comparing one or more drugs with lifestyle modification, placebo, or another drug. RESULTS: This network meta-analysis comprised 262 trials (99 791 participants) evaluating 19 drugs with follow-up from 12 to 172 weeks. Compared with lifestyle modification alone, at one year, moderate to high certainty evidence shows substantial weight loss with tirzepatide (mean difference -14.9%, 95% confidence interval -16.0% to -13.9%), cagrilintide-semaglutide (CagriSema, -14.8%, -16.9% to -12.7%), oral semaglutide (-10.9%, -12.7% to -9.1%), orforglipron (-9.9%, -12.4% to -7.5%), subcutaneous semaglutide (-9.8%, -10.6% to -9.1%), and phentermine-topiramate (-8.1%, -9.7% to -6.5%). Emerging agents (ecnoglutide, mazdutide, retatrutide) may produce similar or greater reductions (13.1-14.6%; very low to low certainty). Moderate to high certainty evidence supports discontinuation because of adverse events to be highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide (risk ratios from 1.9 to 4.2); gastrointestinal events were most increased with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide (risk ratios from 3.1 to 4.2). Fatigue risk increased, particularly with naltrexone-bupropion (risk ratio 8.9; absolute increase 331 per 1000 people over one year), orforglipron (3.4; 100 more per 1000), and CagriSema (3.2; 92 more per 1000). Tirzepatide reduced fat mass the most (by 25.7%) but also lean mass the most (by 8.3%). Subcutaneous semaglutide was the only drug associated with reduced all cause mortality (risk ratio 0.81, 95% confidence interval 0.72 to 0.93) and myocardial infarction (0.72, 0.61 to 0.85), with these estimates largely informed by cardiovascular outcome trials in high risk populations. Subcutaneous semaglutide (0.43, 0.21 to 0.84) and tirzepatide (0.49, 0.27 to 0.88) reduced heart failure risk. No drugs convincingly reduced kidney failure or improved quality of life (43 trials with 45 663 participants) beyond established minimally important differences (all mean differences <5 points; minimally important difference 10). Except for larger weight reductions in trials with longer duration (shown for subcutaneous semaglutide), subgroup analyses for drug dosages and key patient characteristics did not identify credible differences in relative effects of treatment. CONCLUSIONS: Obesity drugs produce variable weight loss at one year, with larger benefits generally accompanied by greater harms and discontinuation. Most agents do not improve quality of life meaningfully and few show cardiovascular benefits. Decisions in clinical practice should consider trade-offs between benefits and harms within the context of shared decision making. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024507993.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
4秒前
面包恐龙完成签到,获得积分10
4秒前
4秒前
RolfHoward完成签到,获得积分10
4秒前
4秒前
小赵爱漂亮完成签到 ,获得积分10
5秒前
羊_完成签到,获得积分10
5秒前
7秒前
傻子发布了新的文献求助20
8秒前
8秒前
8秒前
Twinkle发布了新的文献求助10
9秒前
SciGPT的应助被威武的皮卡丘采纳,获得10
9秒前
秋风的应助被Linkkk采纳,获得10
9秒前
10秒前
完美世界的应助被科研通管家采纳,获得10
10秒前
yang完成签到 ,获得积分10
10秒前
CarryLJR的应助被科研通管家采纳,获得10
10秒前
10秒前
Hello的应助被科研通管家采纳,获得10
10秒前
DW的应助被科研通管家采纳,获得10
10秒前
酷波er的应助被科研通管家采纳,获得10
10秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
10秒前
今后的应助被科研通管家采纳,获得10
10秒前
n01W97的应助被科研通管家采纳,获得20
11秒前
11秒前
Maestro_S的应助被科研通管家采纳,获得10
11秒前
传奇3的应助被科研通管家采纳,获得10
11秒前
江就的应助被科研通管家采纳,获得10
11秒前
11秒前
李爱国的应助被科研通管家采纳,获得10
11秒前
11秒前
11秒前
我是老大的应助被科研通管家采纳,获得10
11秒前
科目三的应助被科研通管家采纳,获得10
11秒前
传奇3的应助被科研通管家采纳,获得10
12秒前
12秒前
13秒前
MAX发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189382
求助须知:如何正确求助?哪些是违规求助? 9576691
关于积分的说明 21849410
捐赠科研通 7787318
什么是DOI,文献DOI怎么找? 3435538
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509